Does Nivolumab Come in Pill Form?
Nivolumab (Opdivo) is only approved and available as an intravenous (IV) infusion. No oral pill formulation exists or is in clinical use.[1]
Why Is Nivolumab Given IV Instead of as a Pill?
Nivolumab is a monoclonal antibody—a large protein molecule that cannot be absorbed effectively through the gut if taken orally. Pills would degrade it or prevent it from reaching the bloodstream intact. IV delivery ensures full bioavailability directly into the veins.[1][2]
How Effective Is IV Nivolumab?
IV nivolumab, dosed every 2–4 weeks, shows response rates of 20–40% in advanced melanoma, lung cancer, and other approved uses, with overall survival benefits in trials like CheckMate 067 (median OS 72 months vs. 39 for ipilimumab).[2][3]
Are There Oral Alternatives to IV Nivolumab?
Oral PD-1/PD-L1 inhibitors exist as competitors:
- Dostarlimab-gxly (Jemperli): IV like nivolumab.
- No direct oral PD-1 equivalent matches nivolumab's profile.
- Inhibitors like pembrolizumab (Keytruda) are also IV; oral kinase inhibitors (e.g., gefitinib) target different pathways and have lower efficacy in immunotherapy settings (response rates <15% vs. nivolumab's).[3][4]
| Drug | Form | Key Indications | Response Rate (example) |
|------|------|-----------------|-------------------------|
| Nivolumab | IV | Melanoma, NSCLC | 40% (melanoma) [2] |
| Pembrolizumab | IV | Similar | 33–42% (NSCLC) [3] |
| Oral alternatives (e.g., osimertinib) | Pill | EGFR+ NSCLC only | 80% but not PD-1 mechanism [4] |
Ongoing Research on Oral Immunotherapies?
Early trials explore oral PD-1 inhibitors (e.g., GS-5718 by Gilead), but none match nivolumab's efficacy data yet. Phase 1 results show tolerability but unproven survival benefits; no head-to-head comparisons exist.[5]
[1]: [FDA Label - Opdivo](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125554s ws.pdf)
[2]: CheckMate 067 Trial - NEJM
[3]: Keytruda vs. Opdivo Comparison - ASCO Data
[4]: Osimertinib FLAURA Trial - NEJM
[5]: Oral PD-1 Inhibitors Pipeline - ClinicalTrials.gov